Camlin Fine Sciences Limited (BOM:532834)
India · Delayed Price · Currency is INR | Market Cap | 20.38B -48.5% |
| Revenue (ttm) | 18.35B +7.4% |
| Net Income | 58.82M |
| EPS | 0.31 |
| Shares Out | 192.09M |
| PE Ratio | 346.48 |
| Forward PE | 21.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,554 |
| Open | 109.55 |
| Previous Close | 109.65 |
| Day's Range | 105.50 - 111.05 |
| 52-Week Range | 96.30 - 234.00 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 152.50 (+43.73%) |
| Earnings Date | Aug 11, 2026 |
About Camlin Fine Sciences
Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hy... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for 532834 stock is "Buy." The 12-month stock price target is ₹152.50, which is an increase of 43.73% from the latest price.
News
Camlin Fine Sciences Transcript: Q1 26/27
Revenue grew 28% year-over-year, but margins were sharply impacted by high raw material and freight costs, with gross margin dropping to 4%. Guidance for FY27 is maintained at INR 2,200–2,300 crore revenue and 10–11% EBITDA margin, with improvement expected from Q3 as input costs stabilize.
Camlin Fine Sciences Quarterly report: Q1 2027
Camlin Fine Sciences has published its Q1 2027 quarterly earnings report on August 11, 2026.
Camlin Fine Sciences Slides: Q1 2027
Camlin Fine Sciences has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 11, 2026.
Camlin Fine Sciences Transcript: Q4 25/26
Revenue and EBITDA were impacted by global logistics and raw material costs, but discontinued operations and tariff reductions improved profitability. FY 2027 guidance remains strong, with vanillin and blends segments expected to drive growth and margins.
Camlin Fine Sciences Quarterly report: Q4 2026
Camlin Fine Sciences has published its Q4 2026 quarterly earnings report on May 26, 2026.
Camlin Fine Sciences Slides: Q4 2026
Camlin Fine Sciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 26, 2026.
Camlin Fine Sciences Annual report: Q4 2026
Camlin Fine Sciences has published its Q4 2026 annual report on May 26, 2026.
Camlin Fine Sciences Transcript: Q3 25/26
Q3 revenue grew 6% year-over-year to INR 572 crore, with blends up 11% and vanillin sales managed for tariff optimization. FY 2027 guidance targets 4,000 tons vanillin, 25% blends growth, and improved margins, while liquidation of European and Chinese subsidiaries aims to halt cash losses.
Camlin Fine Sciences Quarterly report: Q3 2026
Camlin Fine Sciences has published its Q3 2026 quarterly earnings report on February 13, 2026.
Camlin Fine Sciences Slides: Q3 2026
Camlin Fine Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 13, 2026.
Camlin Fine Sciences Transcript: Q2 25/26
Quarterly revenue grew 8.6% sequentially, led by strong volume recovery in trades and blends, with vanillin sales up 35% but realizations pressured by tariffs. Management reaffirmed full-year sales and volume guidance, with growth supported by field force expansion and a new French acquisition.
Camlin Fine Sciences Quarterly report: Q2 2026
Camlin Fine Sciences has published its Q2 2026 quarterly earnings report on November 10, 2025.
Camlin Fine Sciences Slides: Q2 2026
Camlin Fine Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 10, 2025.
Camlin Fine Sciences Q3 FY25 results: Revenue rises 8.7% YoY to Rs 435.5 crore, net loss at Rs 158.2 crore
The company attributed the net loss to several factors, including impairments on overseas subsidiaries, non-cash adjustments, and foreign exchange losses.
Top stocks to buy today: Stock recommendations for February 7, 2025
Stock market recommendations: Bajaj Broking Research recommends buying Camlin Fine Sciences and Equinox India Developments for favorable stock positions. The Nifty is expected to sustain a positive bi...